EVAX Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 404.76%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Evaxion AS, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Evaxion AS.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Evaxion AS's net income of -$1.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Evaxion AS's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.74x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -64.14% compared to Evaxion AS's net margin of -170.14%. Evaxion AS's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 404.76%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 188.95%. Given that Evaxion AS has higher upside potential than Cellectis SA, analysts believe Evaxion AS is more attractive than Cellectis SA.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are smaller than Cellectis SA quarterly revenues of $10.7M. Evaxion AS's net income of -$1.6M is higher than Cellectis SA's net income of -$18.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.74x versus 4.08x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -64.14% compared to Evaxion AS's net margin of --. Evaxion AS's return on equity of -- beat DBV Technologies SA's return on equity of --.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 404.76%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that Evaxion AS has higher upside potential than DBV Technologies SA, analysts believe Evaxion AS is more attractive than DBV Technologies SA.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evaxion AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Evaxion AS quarterly revenues are $3M, which are larger than DBV Technologies SA quarterly revenues of --. Evaxion AS's net income of -$1.6M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Evaxion AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.74x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -64.14% compared to Evaxion AS's net margin of 37.18%. Evaxion AS's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

Evaxion AS has a consensus price target of $13.25, signalling upside risk potential of 404.76%. On the other hand Novo Nordisk AS has an analysts' consensus of $86.41 which suggests that it could grow by 28.89%. Given that Evaxion AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion AS is more attractive than Novo Nordisk AS.

Evaxion AS has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.798%.

Evaxion AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.48% to investors and pays a quarterly dividend of $1.14 per share. Evaxion AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evaxion AS quarterly revenues are $3M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Evaxion AS's net income of -$1.6M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Evaxion AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 19.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evaxion AS is 1.74x versus 6.85x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.